Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +441494 818 026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+441494 818 026

Testimonials
Zenopa is very professional and also shows a genuine personal interest in the people it works with. I appreciated that they really “Talk-the-Talk” and you can rely on them.
Karel, 2014

Bristol-Myers Squibb and Pfizer report positive Eliquis data

23 June 2011 00:00 in Pharmaceutical Company Product News


Bristol-Myers Squibb and Pfizer have revealed that their collaboratively-developed drug Eliquis has demonstrated efficacy among atrial fibrillation (AF) patients in a new clinical trial.

The drug has been trialled in a phase III study called Aristotle, which evaluated the apixaban compound as a means of treating AF sufferers with an elevated risk of stroke.

Eliquis was able to meet its primary goal of non-inferiority to warfarin in preventing stroke and systemic embolism, as well as its secondary endpoint of superior efficacy and reduction of major bleeding events compared to the control drug.

The partners intend to present detailed data on the Aristotle outcome at this year's European Society of Cardiology Congress, which takes place in Paris in August.

European and US regulatory filings will also be submitted for Eliquis in this specification in the third or fourth quarter of 2011.

This comes after Bristol-Myers Squibb and Pfizer received their first regulatory approval for the drug last month, when the European Commission ratified it as a treatment for venous thromboembolic events among orthopaedic surgery patients.ADNFCR-8000103-ID-800591566-ADNFCR

Other news stories from 23/06/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd